Effect of omega 3 fatty acids plus low-dose aspirin on both clinical and biochemical profiles of patients with chronic periodontitis and type 2 diabetes: a randomized double blind placebo-controlled study

• Published in: Journal of periodontal research Vol. 50; no. 6; pp. 721 - 729
• Main Authors: Elwakeel, N. M., Hazaa, H. H.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.12.2015
• Subjects: Adult; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Aspirin - administration & dosage; Biomarkers - analysis; Chemokine CCL7 - analysis; chronic periodontitis; Chronic Periodontitis - drug therapy; Chronic Periodontitis - pathology; Diabetes Mellitus, Type 2 - complications; Double-Blind Method; Fatty Acids, Omega-3 - administration & dosage; Female; Gingival Crevicular Fluid - chemistry; Humans; Male; Middle Aged; monocyte chemoattractant protein-3; omega 3; Placebos - administration & dosage; type 2 diabetes; Young Adult; monocyte chemoattractant protein-3; type 2 diabetes; chronic periodontitis; omega 3
• ISSN: 0022-3484; 1600-0765; 1600-0765
• DOI: 10.1111/jre.12257

Background and Objectives The aim of this study was, first, to investigate the effect of omega 3 (ω3) fatty acids plus low‐dose aspirin with closed debridement in the treatment of patients with periodontitis and type 2 diabetes mellitus (DM), and second, to estimate the expression of monocyte chemoattractant protein‐3 (MCP‐3) in response to the supposed modulatory therapy. Material and Methods Forty patients with chronic periodontitis and type 2 DM were equally divided into groups 1 (patients received ω3 plus low‐dose aspirin for 6 mo) and 2 (patients received placebo during the same period). Evaluation was done clinically (pocket depth, clinical attachment loss, gingival index and plaque index) and biochemically by estimating levels of interleukin 1β and MCP‐3 in gingival crevicular fluid, plus investigating the effect of treatment on glycemic control by levels of glycated hemoglobin A1c in serum. All data were collected at baseline, 3 and 6 mo after treatment. Results Subjects of group 1 showed a highly significant reduction in pocket depth, clinical attachment loss, gingival index (p ≤ 0.01) after 3 and 6 mo compared to group 2. Glycated hemoglobin A1c levels showed a reduction in both groups at the end of the study period, with a non‐significant difference (p > 0.05). Furthermore, the treatment protocol showed a significant reduction in levels of MCP‐3 and interleukin 1β at 3 and 6 mo compared to the placebo group. Conclusions Within the limits of the present study, ω3 plus low‐dose aspirin proved effective as an adjunct to closed periodontal therapy in the management of patients with periodontitis and type 2 DM. Moreover, MCP‐3 was proven to be effective both in the pathogenesis of the disease and as a biomarker in evaluating the response to periodontal treatment.